A&D HOLON Holdings (7745) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 ended March 2026, revenue increased but profit declined due to persistently high selling, general and administrative expense burdens. Revenue was ¥48.63B (¥48.12B in the same period last year, +1.1%), Operating Income was ¥5.65B (¥6.05B, -6.7%), Ordinary Income was ¥5.83B (¥6.20B, -6.0%), and Net Income attributable to owners of the parent was ¥3.40B (¥3.99B, -14.8%). The primary factor behind the deterioration in profit margins was the decline in profit from the core Medical and Healthcare Equipment Business due to U.S. tariffs and higher selling costs.

Factors Affecting Performance

【Revenue】Revenue was ¥48.63B, representing a slight increase of +1.1% year on year. The Semiconductor-Related Business declined by 5.7% to ¥8.42B as the demand adjustment phase continued, while the Measurement and Weighing Instruments Business increased by +0.3% to ¥26.90B on firm demand in Japan and China. The Medical and Healthcare Equipment Business increased by +5.4% to ¥34.25B, supported by strong U.S. demand for medical equipment and special-demand projects for healthcare equipment. Overseas, the Medical and Healthcare Equipment Business expanded in the Americas and Europe, while the same business in Japan declined year on year, indicating a change in the regional mix.

【Profit and Loss】Operating Income was ¥5.65B, down -6.7% year on year, and the Operating Income margin deteriorated to 11.6% from the same period last year. Although the gross margin was maintained at 45.0%, the SG&A ratio of 33.4% weighed on the profit margin. The largest factor behind the decline in profit was the -15.5% decrease in segment profit for the core Medical and Healthcare Equipment Business due to U.S. tariffs and higher selling costs. Extraordinary losses of ¥0.56B (including losses on disposal of fixed assets) were a temporary factor that weakened the conversion from Profit Before Tax to Net Income, causing the decline in Net Income (-14.8%) to exceed the decline in Operating Income (-6.7%). Overall, the Company recorded higher revenue but lower profit.

Segment Analysis

On a segment-profit basis, the Medical and Healthcare Equipment Business was the largest at ¥2.95B, accounting for approximately 40% of the total and representing the core business. Segment profit declined by -15.5% year on year due to U.S. tariffs and higher selling costs, creating the largest headwind for company-wide profit. The Measurement and Weighing Instruments Business returned to profit growth, increasing by +14.1% to ¥1.59B, as measures to improve the profitability of DSP equipment proved effective. The Semiconductor-Related Business declined by -9.0% to ¥2.83B; although its profit margin was the highest among all segments at 33.6%, it fell from its previous level as the demand adjustment phase continued. By region, the Measurement and Weighing Instruments Business in the Americas recorded an Operating Loss of ¥0.17B (profit margin of -4.7%), indicating substantial differences in profit margins among segments.

Key Financial Indicators

Profitability: ROE was 7.3%, and the Operating Income margin was 11.6%, down from approximately 12.6% in the same period last year.
Financial soundness: The Equity Ratio was 64.4% (up from 61.9% in the same period last year), and the current ratio was 231.4%.
Earnings per share: EPS was ¥124.04 (¥145.07 in the same period last year, -14.5%).
Working capital: Accounts receivable of ¥16.72B and inventories of ¥11.58B are large relative to the asset base and are factors restraining capital efficiency.

Cash Flow Analysis

Although detailed figures from the statement of cash flows were not included in the disclosed data, the working capital structure—accounts receivable of ¥16.72B, inventories of ¥11.58B, and accounts payable of ¥4.10B—suggests that revenue growth is unlikely to translate directly into cash generation. Cash and deposits were ¥12.56B, down -5.9% year on year, indicating that the accumulation of working capital may be affecting funding efficiency. With respect to capital expenditure, the completion of a new plant was mentioned, and property, plant and equipment increased to ¥14.13B from ¥12.88B in the same period last year.

Earnings Quality

Net Income of ¥3.40B diverged from Ordinary Income of ¥5.83B, primarily due to income taxes of ¥1.86B (an effective tax rate of approximately 35.2%) and extraordinary losses of ¥0.56B. Non-operating income of ¥0.67B was limited to 1.4% of revenue, indicating only a limited divergence from recurring operating results. Extraordinary losses were primarily related to losses on disposal of fixed assets and other items and were non-recurring, contributing to the decline in Net Income exceeding the decline in Operating Income.

Earnings Forecast and Guidance

Progress toward the full-year forecast (Revenue of ¥70.00B, Operating Income of ¥9.50B, and Ordinary Income of ¥9.40B) was 69.5% for revenue, 59.5% for Operating Income, and 62.0% for Ordinary Income, below the standard 75% progress level. In particular, Operating Income would need to accumulate an additional ¥2.95B in Q4, and progress is somewhat behind schedule even after considering seasonality. The launch of the new semiconductor product HSS-1000, the start-up of the new plant, and continued profitability improvement for DSP products in the Measurement and Weighing Instruments Business will be key to profit recovery in the second half.

Shareholder Returns

The Q2 dividend was ¥25.00 per share, meaning that half of the full-year company forecast of annual dividends of ¥50.00 has already been paid. Based on the company forecast of Net Income attributable to owners of the parent of ¥6.50B, the Payout Ratio is approximately 21.1%, indicating a light dividend burden relative to the Net Income level. No share repurchase activity could be confirmed from the disclosed data, and this report therefore presents only the Payout Ratio.

Catalysts

【Short term】Normalization of the profitability of the Medical and Healthcare Equipment Business in Q4, demand trends in the Semiconductor-Related Business, and the extent to which the full-year earnings forecast is achieved. 【Long term】Market penetration of the new semiconductor product HSS-1000 and production ramp-up at the new plant, expansion of global market coverage for the Medical and Healthcare Equipment Business, and progress in price optimization and supply chain efficiency improvements in response to U.S. tariffs.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

The Company's profitability is above the median level for the manufacturing industry.

Growth and Capital Efficiency

The revenue growth rate is below the industry median, indicating that top-line expansion is relatively gradual.

※Source: Compiled by the Company

Risk Factors

1. Prolonged demand adjustment in the Semiconductor-Related Business: Revenue declined by 5.7% year on year to ¥8.42B, while segment profit declined by 9.0% to ¥2.83B, with lower revenue and profit continuing. Performance is therefore subject to customers' capital expenditure cycles.

2. Deterioration in the profitability of the core business: The Medical and Healthcare Equipment Business recorded higher revenue (+5.4%), but segment profit declined by -15.5%. U.S. tariffs and higher selling costs were the primary factors, and the progress of price pass-through and cost management will be key areas of focus going forward.

3. Working capital efficiency: Accounts receivable of ¥16.72B and inventories of ¥11.58B account for approximately 39% of total assets (¥72.26B), and trends in collection and inventory efficiency could affect capital efficiency.

Key Takeaways from the Earnings Results

1. Although the Operating Income margin of 11.6% exceeds the industry median, it declined from the same period last year, indicating that the decline in profit from the core Medical and Healthcare Equipment Business is affecting the trend in company-wide profitability.

2. The Measurement and Weighing Instruments Business returned to profit growth, with segment profit increasing by +14.1%. The effectiveness of measures to improve the profitability of DSP equipment can be confirmed as a supporting factor within the portfolio.

3. Progress toward the full-year forecast was 59.5% for Operating Income and below the standard progress level even on a Net Income basis. The pace of profit recovery in Q4 will be a key point to monitor in assessing achievement of the full-year plan.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,916–¥2,032 at ±1% for the cost of equity, and ¥1,966–¥1,983 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these are not forecasts of market share prices or recommendations of any specific investment action and do not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated through AI-integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional advisor as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 performance was mixed: revenue grew modestly, but profitability and net income weakened as gross-margin pressure and a large extraordinary loss outweighed improved non-operating income. Revenue increased 1.1% YoY to ¥48.63bn. Operating income declined 6.7% YoY to ¥5.65bn, while ordinary income fell 6.0% to ¥5.83bn. Net income attributable to owners dropped 14.8% to ¥3.40bn, equivalent to basic EPS of ¥124.04. Gross profit decreased 0.9% to ¥21.90bn despite higher sales. The gross margin compressed by 88bp YoY to 45.0% from 45.9%. Operating margin declined by 97bp to 11.6% from 12.6%, remaining in the good range but indicating weaker operating leverage. SG&A increased 1.4% to ¥16.25bn, slightly faster than revenue growth, contributing to the operating-income decline. Non-operating income rose to ¥0.67bn, led by ¥0.41bn of interest income and ¥0.16bn of foreign-exchange gains. However, a ¥0.56bn extraordinary loss reduced profit before tax by 15.0% YoY to ¥5.27bn. The effective tax rate was 35.2%, producing a tax burden of 0.644 and further limiting conversion of pre-tax earnings into net income. Comprehensive income increased 33.2% YoY to ¥5.01bn, supported principally by favorable foreign-currency translation adjustments of ¥1.59bn. Medical and healthcare equipment remained the core earnings contributor, although its segment profit fell materially. Measurement and weighing equipment posted a profit recovery, but semiconductor-related operations declined in both revenue and profit. The balance sheet remains well capitalized, with equity of ¥46.55bn and a 64.3% capital adequacy ratio. Liquidity is ample at the aggregate level, but the ¥11.48bn concentration of short-term loans creates an ongoing refinancing requirement. Working-capital intensity is the principal operating concern, with elevated receivable, inventory and cash-conversion-cycle alerts. Full-year guidance requires a substantial Q4 acceleration, particularly in operating profit and net income, making delivery dependent on margin recovery, inventory conversion and a stronger second-half sales mix.

Profitability Analysis

The reported annualized DuPont ROE is 9.7%, decomposed into a 7.0% net profit margin, 0.897x asset turnover and 1.55x financial leverage. Profitability is therefore supported more by operating returns than by aggressive balance-sheet leverage, as financial leverage remains moderate. The most significant YoY change was margin compression: gross margin fell 88bp to 45.0% and operating margin fell 97bp to 11.6%. This indicates that the modest 1.1% revenue increase did not translate into incremental operating profit. SG&A rose 1.4%, exceeding revenue growth and creating mild negative operating leverage. EBIT margin of 11.6% remains solid for a diversified precision-equipment manufacturer, but it is below the prior-year level. The five-factor DuPont structure shows an interest burden of 0.934, demonstrating limited earnings drag from financing costs despite the sizable short-term debt balance. Interest coverage is strong at 25.91x, consistent with operating income comfortably covering ¥0.22bn of interest expense. The tax burden of 0.644 reflects the 35.2% effective tax rate and is a more meaningful constraint on net-income conversion than interest expense. The decline in net income was steeper than the operating-income decline because profit before tax included a ¥0.56bn extraordinary loss. Segment performance was uneven: semiconductor-related business delivered a high 33.6% segment margin but suffered a 123bp YoY margin decline, while medical and healthcare equipment saw a 390bp decline in segment margin to 15.6%. Measurement and weighing equipment improved its segment margin by approximately 90bp to 7.5%, providing a partial offset. The sustainability of group margin recovery depends primarily on normalization in medical and healthcare profitability and a recovery in semiconductor-related demand rather than on higher financial leverage.

Growth Assessment

Revenue growth of 1.1% YoY was modest and reflected divergent segment trends. Semiconductor-related revenue declined 5.7% YoY to ¥8.42bn, while segment profit fell 8.9% to ¥2.83bn. Its profit margin remained the highest among reporting segments at 33.6%, but the sales decline leaves earnings exposed to semiconductor capital-spending cycles. Measurement and weighing equipment revenue was broadly flat, increasing 0.3% to ¥21.32bn. Segment profit in this business increased 14.1% to ¥1.59bn, indicating improved operating efficiency despite limited top-line growth. Medical and healthcare equipment was the largest segment by operating-income contribution and therefore the core business, generating segment profit of ¥2.95bn. Medical and healthcare revenue rose 5.4% to ¥18.90bn, but segment profit declined 15.5% YoY from ¥3.49bn. The core business's segment margin declined to 15.6% from 19.4%, making its margin recovery central to the group earnings outlook. Within medical and healthcare equipment, overseas revenue growth was favorable: Americas revenue increased 7.1%, Europe increased 14.6%, and Asia-Oceania increased 17.3%. This overseas expansion partly offset a 16.5% decline in Japanese medical and healthcare revenue. Measurement and weighing equipment also showed stable international demand, though Americas sales declined 7.1% and Europe declined 8.5%. The FY2026 forecast calls for revenue of ¥70.0bn, operating income of ¥9.5bn and net income attributable to owners of ¥6.5bn. Q3 cumulative progress is 69.5% for sales, 59.5% for operating income, 62.0% for ordinary income and 52.2% for net income, compared with a standard 75% at Q3. Each profit-progress measure is more than 10 percentage points below the standard pace. Achieving guidance would require Q4 revenue of ¥21.37bn and operating income of ¥3.85bn, implying a Q4 operating margin of approximately 18.0%, versus 11.6% cumulatively through Q3. The forecast therefore embeds a marked fourth-quarter margin improvement and a recovery in profit conversion.

Financial Health

Financial health is fundamentally sound, supported by total equity of ¥46.55bn, a capital adequacy ratio of 64.3% and total liabilities representing 35.6% of assets. The current ratio of 231.4% and quick ratio of 181.5% indicate strong balance-sheet liquidity. Working capital was ¥30.50bn, providing a substantial buffer against current liabilities. Debt-to-equity was a conservative 0.55x, well below the 2.0x level associated with aggressive leverage. Debt-to-capital was also moderate at 20.1%. Interest-bearing debt totaled ¥11.69bn, compared with cash and deposits of ¥12.56bn, leaving net cash of approximately ¥0.57bn. Interest coverage of 25.91x indicates a strong ability to service current borrowing costs. The material capital-structure issue is maturity concentration: 98.3% of interest-bearing debt is short term, with short-term loans of ¥11.48bn and long-term loans of only ¥0.20bn. This directly addresses the refinancing-risk alert: the root cause is reliance on short-dated funding rather than the overall level of leverage. Aggregate liquidity reduces immediate maturity-mismatch risk because current assets are ¥53.72bn and cash alone covers short-term loans by 1.09x. Nevertheless, cash coverage is only modest once operating-cash requirements are considered, so continued bank-market access and rollover capacity remain important. Long-term loans decreased by ¥1.06bn YoY, or 83.9%, while short-term loans increased by ¥0.40bn, reinforcing the shift toward short-term funding. Goodwill increased from ¥0.003bn to ¥0.068bn following a small acquisition-related addition, but goodwill remains only 0.1% of both equity and total assets. The balance sheet is therefore not materially exposed to goodwill impairment risk. Defined-benefit obligations of ¥1.10bn and product-warranty provisions of ¥0.30bn are manageable relative to the equity base and liabilities.

Notable B/S Changes

Goodwill: +¥0.65bn (+2,166.7%) to ¥0.68bn — indicates a small acquisition-related addition, but goodwill remains immaterial at 0.1% of equity and impairment exposure is limited. Long-term loans: -¥1.06bn (-83.9%) to ¥0.20bn — materially reduces long-dated debt but reinforces the short-term refinancing concentration. Inventories: +¥1.82bn (+18.7%) to ¥11.58bn — materially outpaced revenue growth and is consistent with the elevated inventory-day and cash-conversion-cycle alerts. Work in process: +¥0.92bn (+21.0%) to ¥5.29bn — indicates greater capital tied up in production, increasing the importance of shipment timing and production throughput. Property, plant and equipment: +¥1.25bn (+9.4%) to ¥14.13bn — reflects an increased fixed-asset base, with PPE representing 19.6% of total assets. Total equity: +¥3.75bn (+8.8%) to ¥46.55bn — strengthened by retained earnings growth and favorable foreign-currency translation effects. Foreign-currency translation adjustment: +¥1.58bn to ¥1.09bn from a negative ¥0.49bn — improved equity and comprehensive income but introduces sensitivity to future exchange-rate reversals.

Cash Flow Quality

Working-capital efficiency is the key cash-conversion risk in the current period. Accounts receivable increased 0.9% YoY to ¥16.72bn, despite revenue growth of only 1.1%, leaving a high receivables base relative to sales. The quality alert reports receivable days of 94 days, above the 60-day warning level; annualizing the reported Q3 cumulative sales produces an even higher indicative level of approximately 118 days. The root cause is slow collection relative to annualized sales, rather than a deterioration in nominal receivables alone. For a manufacturer selling precision, medical and semiconductor-related equipment, extended customer payment terms and project-based delivery timing can contribute to a longer collection cycle, but the level remains unfavorable versus manufacturing benchmarks. The impact is greater funding needs and reduced flexibility to convert accounting revenue into cash. Inventories rose 18.7% YoY to ¥11.58bn, substantially outpacing sales growth. Finished goods were ¥11.58bn, while raw materials were ¥5.73bn and work in process was ¥5.29bn. The reported inventory-day alerts of 231 days and 119 days both exceed their respective warning thresholds of 90 days and 60 days. The 119-day alert is consistent with inventory days calculated from annualized cost of sales, while the 231-day alert indicates an additional, more conservative inventory-cycle measure; both identify elevated inventory intensity. The root cause is inventory accumulation relative to production cost and sales throughput. This may reflect strategic component stocking, delayed customer shipments, demand normalization or slower product turnover, but it raises obsolescence and margin-risk exposure in technology-sensitive product categories. The reported cash conversion cycle of 284 days is well above the 120-day warning threshold, reflecting the combined burden of receivables and inventory. Accounts payable increased only 3.2% YoY to ¥4.10bn and therefore did not offset the build in operating working capital. The impact of the long cash conversion cycle is that future earnings quality and free-cash-flow conversion will depend heavily on collection discipline and inventory reduction. No cash-flow figures are used in this assessment; the analysis is based on reported balance-sheet working-capital indicators.

Dividend Sustainability

The company paid an interim Q2 dividend of ¥25.00 per share and forecasts a full-year dividend of ¥50.00 per share. The calculated interim payout ratio was 20.5% of Q3 cumulative net income. Based on forecast EPS of ¥237.45, the full-year dividend implies a dividend-only payout ratio of approximately 21.1%. This is conservative relative to the 60% sustainability benchmark and leaves considerable retained earnings capacity. Retained earnings increased to ¥30.98bn from ¥28.83bn a year earlier, supporting dividend capacity. The low payout burden is also supported by the company's moderate debt-to-equity ratio of 0.55x and net-cash position. However, cash conversion should be monitored because elevated receivables and inventory increase the amount of capital tied up in operations. The dividend outlook is therefore financially conservative on an earnings basis, while the durability of cash coverage will depend on working-capital normalization and delivery of the forecast profit recovery.

Risk Assessment

Business risks include High priority — Semiconductor-related revenue declined 5.7% YoY and segment profit declined 8.9%; the business retains a high 33.6% margin, so further semiconductor-capex weakness could have a disproportionate effect on group profitability., High priority — Medical and healthcare equipment, the core earnings business, experienced a 15.5% decline in segment profit despite 5.4% revenue growth. The 390bp margin contraction suggests cost, mix or execution pressure that must reverse for group guidance to be achieved., High priority — Inventory intensity is elevated. The reported DIO alerts of 231 days and 119 days both exceed warning thresholds, creating risks of inventory obsolescence, discounting, lower production utilization and future gross-margin pressure., Medium priority — Receivable days of 94 days in the quality alert, and approximately 118 days on an annualized-sales calculation, point to slow cash collection. This may be partly characteristic of equipment and project sales but raises the risk of delayed cash realization and credit losses., Medium priority — A 284-day cash conversion cycle is materially above the 120-day warning threshold. The combination of slow collections and high inventory can constrain funding capacity during demand slowdowns., Medium priority — Foreign operations create currency sensitivity. The period included ¥0.16bn of FX gains and ¥1.59bn of favorable foreign-currency translation OCI, indicating that exchange-rate movements can affect both reported earnings and equity..

Financial risks include High priority — Refinancing risk is elevated because 98.3% of interest-bearing debt is short term. The root cause is ¥11.48bn of short-term loans versus only ¥0.20bn of long-term loans. This structure is not excessive leverage in absolute terms, but it requires regular refinancing and could expose the company to tighter bank terms or higher rates., Medium priority — Cash-to-short-term-debt is 1.09x. This provides nominal coverage, but the margin is narrower after considering operating working-capital needs, particularly given high receivables and inventories., Low priority — The effective tax rate of 35.2% and tax burden of 0.644 reduced conversion of pre-tax income into net income. This is not a solvency issue but increases earnings sensitivity when pre-tax profit weakens., Low priority — The ¥0.56bn extraordinary loss was significant relative to the ¥3.40bn net income attributable to owners, increasing below-the-line earnings volatility..

Key concerns include The key near-term issue is the gap between Q3 cumulative operating-income progress of 59.5% and the 75% standard pace implied by full-year guidance., Guidance requires an implied Q4 operating margin of approximately 18.0%, materially above the 11.6% Q3 cumulative margin., The high receivable-days alert must be viewed alongside the high-inventory-days alerts and 284-day CCC: together they signal a potentially material cash-conversion challenge rather than isolated balance-sheet movements., The refinancing-risk alert is mitigated by a 231.4% current ratio, 181.5% quick ratio and strong 25.91x interest coverage, but the maturity profile remains a structural risk to monitor., Goodwill rose 2,166.7% YoY but from a very small base; at 0.1% of equity, it does not alter the financial-risk profile materially..

Investment Implications

Key takeaways include Revenue resilience was limited at 1.1% YoY, while operating income declined 6.7% and net income attributable to owners declined 14.8%., Medical and healthcare equipment is the core business by segment-profit contribution, but its margin deterioration is the largest operational issue., Measurement and weighing equipment delivered the strongest positive earnings surprise within the portfolio, with segment profit up 14.1% on nearly flat revenue., The company has a strong liquidity position and moderate leverage, but its debt maturity profile is overwhelmingly short term., Elevated receivables, inventories and the 284-day cash conversion cycle are the most important indicators for earnings-to-cash conversion., The dividend burden is low at an estimated 21.1% of forecast EPS, preserving financial flexibility., Full-year guidance depends on a substantial Q4 profit recovery and should be evaluated against evidence of margin normalization and working-capital release..

Metrics to watch include Medical and healthcare equipment segment margin, which was 15.6% in FY2026 Q3 versus 19.4% a year earlier., Semiconductor-related revenue and segment margin, which were ¥8.42bn and 33.6%, respectively., Q4 operating margin required to reach guidance, approximately 18.0%., Receivable days, including the reported 94-day alert level., Inventory days, including the reported 231-day and 119-day alert measures., Cash conversion cycle, reported at 284 days., Short-term debt refinancing terms, short-term loan balance and cash-to-short-term-debt coverage., Foreign-exchange effects on ordinary income and OCI..

Regarding relative positioning, A&D Horon Holdings combines a solid 11.6% operating margin, strong interest coverage and conservative balance-sheet leverage with less favorable working-capital efficiency. Its 9.7% annualized ROE is respectable but below the 10%-15% range generally associated with stronger return profiles. The group appears financially more resilient than a highly leveraged manufacturer, but near-term relative performance is likely to be determined by medical-equipment margin recovery, semiconductor-cycle conditions and the ability to convert the enlarged working-capital base into cash.